11/8/2022 6:43:34 AM
Reata Pharma Q3 Non-GAAP Net Loss $53.9 Mln Or $1.47/shr Vs
net Loss Of $46.2 Mln Or $1.27/shr Prior Year
8/9/2022 7:28:29 AM
Reata Pharma Announces Three Month Extension Of Review Period For NDA For Omaveloxolone For Friedreich's Ataxia
8/8/2022 6:49:03 AM
Reata Pharmaceuticals, Inc. Q2 Net Loss/shr $2.02 Vs. Loss/shr $2.00 Last Year
5/26/2022 6:52:44 AM
Reata Pharma Announces FDA Filing Acceptance With Priority Review For Omaveloxolone NDA For Friedreich's Ataxia
5/10/2022 6:44:24 AM
Reata Pharma Q1 GAAP Net Loss $73.8 Mln Or $2.03/Shr Vs Loss Of $67.5 Mln Or $1.86/Shr Last Year
2/28/2022 6:48:42 AM
Reata Pharma FY GAAP Net Loss $297.4 Mln Or $8.19/Shr Vs Loss Of $247.8 Mln Or $7.35/Shr Last Year
1/31/2022 6:49:00 AM
Reata Initiates Rolling Submission Of NDA With FDA For Omaveloxolone For Friedreich's Ataxia Treatment
12/8/2021 7:40:35 AM
Reata Pharma: FDA Advisory Committee To Discuss Bardoxolone For Chronic Kidney Disease Caused By Alport Syndrome